Abstract: Basic research and clinical research on multiple myeloma (MM) have extensively progressed, as proven by the change in the definition of complete response (CR). With improvements in laboratory technology and introduction of novel agents, CR particularly emphasized both micro- and macro-models. The development of CR yielded therapeutic advances in MM and vice versa. The definitions of response and treatment strategies were closely connected and improved. A need exists for further detailed studies on long-term disease control, such as optimal combination of agents. Given the shortage of new drugs and the distinctiveness of health insurance, Chinese doctors should select the best treatment projects based on real-life situation in China.